Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
News Jan 05, 2011
"We believe that adopting IDBS's Bioprocess Execution System as our data management solution will help us improve our processes and enhance the quality of the services we provide to customers," said Dr. Steve Flatman, Head of Mammalian Development Services. "After due consideration the IDBS software and service offering was our preferred solution. The knowledge and expertise of IDBS staff in the bioscience arena was a key factor in our decision."
Due to the complex nature of biopharmaceutical processes, pharmaceutical companies invest considerable time and money generating high-value data throughout the development lifecycle. This information is often locked in paper records or isolated electronic files, across multiple locations and in different formats, making it difficult to manage and analyze process data efficiently. As a result, organizations such as Lonza are turning to data management systems to integrate and optimize bioprocess workflows. This enables management of the complete laboratory-to-report lifecyle within one system, and makes data retrievable by scientists to help in targeting process optimizations. This, in turn, will assist the drive for operational excellence, a core part of Lonza's strategy.
"IDBS continues to develop informatics solutions that address the critical business needs of high value R&D and manufacturing activities," said Neil Kipling, founder and CEO of IDBS. "We believe that the bioprocess sector is an area of considerable growth and will benefit from our broad expertise and industry experience. We are delighted to be working with such an innovative company as Lonza, one of the first contract manufacturers to adopt our approach to process and knowledge management."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE